A century of emergence: trends and patterns in human viral pathogens, 1900-2024, a systematic review.

A century of emergence: trends and patterns in human viral pathogens, 1900-2024, a systematic review.

Publication date: Dec 20, 2025

Emerging infectious diseases (EIDs) pose ongoing global health threats, making it essential to understand their temporal, geographic, and biological patterns to inform prevention and control strategies. We conducted a systematic review of 212 human viruses reported between 1900 and 2024, drawing data from Scopus, PubMed, and grey literature, and applied an adapted PRISMA framework. Temporal trends, geographic origins, modes of transmission, and clinical syndromes were analyzed, complemented by a novel visualization tool for exploring patterns interactively. Viral emergence peaked during 1950-1979 (n = 87) and again since 2000 (n = 52), with the United States (n = 42), China (n = 15), and Australia (n = 10) most frequently reported as initial detection sites, reflecting differences in surveillance and research capacity. RNA viruses, particularly influenza viruses and coronaviruses, dominated emergence events. Vector-borne and zoonotic pathogens accounted for 62% of EIDs. Temporal peaks corresponded with advancements in molecular diagnostics, laboratory infrastructure, and global surveillance networks. We identified 212 viruses, with most emerging between 1950 and 1979 (n = 87) and 52 since 2000. Febrile disease was predominant (27. 4%), with respiratory and hemorrhagic diseases also prevalent. Our findings highlight how technological, ecological, and socio-demographic factors shape viral emergence. The interactive visualization tool provides a resource for understanding historical trends, informing risk assessment, and guiding future surveillance strategies.

Open Access PDF

Concepts Keywords
Australia Emerging infectious diseases
China Human infections
Coronaviruses Reemerging infectious diseases
Laboratory Vector-borne
Virus
Zoonotic

Semantics

Type Source Name
disease MESH Emerging infectious diseases
disease MESH syndromes
disease MESH influenza
disease MESH Infectious Diseases
disease MESH Dis
pathway REACTOME Reproduction
disease MESH included
disease MESH viral diseases
disease MESH infections
disease MESH Zoonotic spillover
pathway REACTOME Infectious disease
disease MESH strains
disease MESH avian influenza
drug DRUGBANK Isoxaflutole
disease MESH Dengue
disease MESH poliomyelitis
disease MESH fever
disease MESH rash
disease MESH encephalitis
disease MESH aids
disease MESH viral encephalitis
drug DRUGBANK Methionine
disease MESH gastrointestinal disease
disease MESH Ebola virus disease
disease MESH Venezuelan equine encephalitis
disease MESH Murray valley encephalitis
disease MESH yellow fever
disease MESH Rift Valley fever
disease MESH West Nile fever
disease MESH Respiratory diseases
disease MESH hepatitis
disease MESH persistent infection
disease MESH smallpox
disease MESH measles
pathway KEGG Measles
drug DRUGBANK Coenzyme M
pathway REACTOME Influenza Infection
disease MESH pneumonia
disease MESH monkeypox
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Emergencies
disease MESH cancer
disease MESH Mumps
drug DRUGBANK Bean
drug DRUGBANK Guanosine
drug DRUGBANK Carboxyamidotriazole
disease MESH SARS CoV 2 infection
disease MESH long COVID
disease MESH Japanese encephalitis
disease MESH Lassa fever
disease MESH Bolivian Hemorrhagic Fever

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *